Sign in or create an account to add this stock to your watchlist.
About Amphastar Pharmaceuticals (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484
Debt
Debt-to-Equity Ratio0.12
Current Ratio2.40
Quick Ratio1.53
Price-To-Earnings
Trailing P/E Ratio43.05
Forward P/E Ratio55.23
P/E Growth2.48
Sales & Book Value
Annual Sales$240.18 million
Price / Sales3.22
Cash Flow$0.7287 per share
Price / Cash22.74
Book Value$7.34 per share
Price / Book2.26
Profitability
EPS (Most Recent Fiscal Year)$0.38
Net Income$4.50 million
Net Margins-1.50%
Return on Equity3.39%
Return on Assets2.52%
Miscellaneous
Employees1,644
Outstanding Shares46,610,000
Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions
What is Amphastar Pharmaceuticals' stock symbol?
Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."
How will Amphastar Pharmaceuticals' stock buyback program work?
Amphastar Pharmaceuticals announced that its Board of Directors has initiated a share repurchase plan on Thursday, August 10th 2017, which authorizes the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's leadership believes its stock is undervalued.
How were Amphastar Pharmaceuticals' earnings last quarter?
Amphastar Pharmaceuticals (NASDAQ:AMPH) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.05) EPS for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.13. The business earned $58.40 million during the quarter, compared to the consensus estimate of $60.75 million. Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.39%. Amphastar Pharmaceuticals's revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the business earned $0.09 EPS. View Amphastar Pharmaceuticals' Earnings History.
What price target have analysts set for AMPH?
6 brokerages have issued 12 month price targets for Amphastar Pharmaceuticals' shares. Their predictions range from $18.00 to $26.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $21.20 in the next twelve months. View Analyst Ratings for Amphastar Pharmaceuticals.
Who are some of Amphastar Pharmaceuticals' key competitors?
Some companies that are related to Amphastar Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are Amphastar Pharmaceuticals' key executives?
Amphastar Pharmaceuticals' management team includes the folowing people:
- Dr. Ziping Luo Ph.D., Chairman of The Board, Chief Scientist and Chief Operating Officer (Age 68)
- Dr. Yongfeng Zhang Ph.D., Chief Exec. Officer, Chief Science Officer and Director (Age 71)
- Mr. Jason B. Shandell, Pres & Director (Age 44)
- Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 50)
- Mr. Rong Zhou, Exec. VP of Production Center (Age 59)
Has Amphastar Pharmaceuticals been receiving favorable news coverage?
News articles about AMPH stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.09 on Accern's scale. They also gave news coverage about the company an impact score of 47.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Amphastar Pharmaceuticals' major shareholders?
Amphastar Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.59%), Dimensional Fund Advisors LP (3.62%), Rothschild Asset Management Inc. (0.68%), JPMorgan Chase & Co. (0.63%), Principal Financial Group Inc. (0.59%) and Cortina Asset Management LLC (0.56%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.
Which major investors are selling Amphastar Pharmaceuticals stock?
AMPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Citigroup Inc., Point72 Asset Management L.P., Fisher Asset Management LLC, Russell Investments Group Ltd. and Rothschild Asset Management Inc.. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.
Which major investors are buying Amphastar Pharmaceuticals stock?
AMPH stock was bought by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Mackay Shields LLC, Dimensional Fund Advisors LP, Matarin Capital Management LLC, Citadel Advisors LLC, Campbell & CO Investment Adviser LLC, A.R.T. Advisors LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Amphastar Pharmaceuticals.
How do I buy shares of Amphastar Pharmaceuticals?
Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amphastar Pharmaceuticals' stock price today?
One share of AMPH stock can currently be purchased for approximately $16.57.
How big of a company is Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals has a market capitalization of $775.19 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.
How can I contact Amphastar Pharmaceuticals?
Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]
MarketBeat Community Rating for Amphastar Pharmaceuticals (AMPH)
MarketBeat's community ratings are surveys of what our community members think about Amphastar Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Amphastar Pharmaceuticals in the last 12 months. Their average twelve-month price target is $21.20, suggesting that the stock has a possible upside of 27.94%. The high price target for AMPH is $26.00 and the low price target for AMPH is $18.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.20 | $21.20 | $20.60 | $20.3333 |
| Price Target Upside: | 27.94% upside | 8.66% upside | 8.88% upside | 6.46% upside |
Amphastar Pharmaceuticals (NASDAQ:AMPH) Consensus Price Target History
Amphastar Pharmaceuticals (NASDAQ:AMPH) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Amphastar Pharmaceuticals (NASDAQ:AMPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 31.50%
Institutional Ownership Percentage: 44.67%
Amphastar Pharmaceuticals (NASDAQ AMPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/15/2018 | Jack Y Zhang | CEO | Buy | 25,000 | $16.08 | $402,000.00 | 2,065,619 |  |
| 3/20/2018 | Jason B Shandell | Insider | Sell | 20,000 | $19.43 | $388,600.00 | 251,372 | |
| 3/15/2018 | Richard K Prins | Director | Sell | 16,598 | $19.90 | $330,300.20 | 45,442 | |
| 3/14/2018 | Jason B Shandell | Insider | Sell | 700 | $20.45 | $14,315.00 | | |
| 3/13/2018 | William J Peters | CFO | Sell | 19,801 | $20.10 | $398,000.10 | | |
| 1/26/2018 | Jason B. Shandell | Insider | Sell | 18,627 | $19.42 | $361,736.34 | | |
| 1/25/2018 | Jason B. Shandell | General Counsel | Sell | 8,661 | $19.26 | $166,810.86 | | |
| 12/19/2017 | Diane G Gerst | EVP | Sell | 523 | $19.48 | $10,188.04 | 30,164 | |
| 12/14/2017 | Stephen B Shohet | Director | Sell | 7,866 | $18.87 | $148,431.42 | 31,982 | |
| 12/12/2017 | Diane G Gerst | EVP | Sell | 523 | $18.96 | $9,916.08 | 30,687 | |
| 12/7/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.34 | $144,189.08 | 31,978 | |
| 12/1/2017 | William J. Peters | CFO | Sell | 6,226 | $19.67 | $122,465.42 | | |
| 11/30/2017 | Stephen B Shohet | Director | Sell | 7,862 | $19.25 | $151,343.50 | 31,978 | |
| 11/28/2017 | Diane G Gerst | EVP | Sell | 523 | $18.15 | $9,492.45 | 31,210 | |
| 11/22/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.94 | $148,906.28 | 31,978 | |
| 11/21/2017 | Diane G Gerst | EVP | Sell | 523 | $18.81 | $9,837.63 | 31,733 | |
| 11/16/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.04 | $141,830.48 | 31,978 | |
| 11/15/2017 | Diane G Gerst | EVP | Sell | 523 | $17.77 | $9,293.71 | 32,256 | |
| 11/9/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.55 | $145,840.10 | 31,978 | |
| 11/7/2017 | Diane G Gerst | EVP | Sell | 523 | $17.93 | $9,377.39 | 32,779 | |
| 11/2/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.37 | $144,424.94 | | |
| 10/26/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.39 | $144,582.18 | 31,978 | |
| 10/24/2017 | Diane G Gerst | EVP | Sell | 523 | $18.29 | $9,565.67 | 33,302 | |
| 10/19/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.34 | $144,189.08 | 31,978 | |
| 10/17/2017 | Diane G Gerst | EVP | Sell | 523 | $18.48 | $9,665.04 | 33,825 | |
| 10/13/2017 | William J Peters | CFO | Sell | 3,026 | $18.56 | $56,162.56 | | |
| 10/12/2017 | Stephen B Shohet | Director | Sell | 7,862 | $18.73 | $147,255.26 | | |
| 10/5/2017 | Diane G Gerst | EVP | Sell | 8,444 | $18.87 | $159,338.28 | | |
| 10/4/2017 | Floyd F Petersen | Director | Sell | 39,312 | $18.59 | $730,810.08 | | |
| 10/2/2017 | Michael A Zasloff | Director | Sell | 63,624 | $18.18 | $1,156,684.32 | 101,879 | |
| 8/15/2017 | Richard K Prins | Director | Sell | 10,000 | $14.81 | $148,100.00 | 33,844 | |
| 8/14/2017 | Richard K Prins | Director | Sell | 5,000 | $14.80 | $74,000.00 | 33,844 | |
| 6/9/2017 | Richard K Prins | Director | Sell | 10,000 | $17.07 | $170,700.00 | 28,844 | |
| 6/1/2017 | Michael A Zasloff | Director | Sell | 15,000 | $17.01 | $255,150.00 | 47,411 | |
| 5/31/2017 | Jason B Shandell | Director | Sell | 11,482 | $16.92 | $194,275.44 | 241,342 | |
| 5/11/2017 | Richard K Prins | Director | Sell | 7,500 | $15.43 | $115,725.00 | 30,500 | |
| 1/3/2017 | Floyd F Petersen | Director | Sell | 400 | $18.61 | $7,444.00 | 58,717 | |
| 12/15/2016 | Diane G Gerst | EVP | Sell | 2,940 | $20.51 | $60,299.40 | 26,195 | |
| 12/5/2016 | Rong Zhou | EVP | Sell | 61 | $20.70 | $1,262.70 | 36,991 | |
| 12/1/2016 | Floyd F Petersen | Director | Sell | 400 | $20.26 | $8,104.00 | 59,117 | |
| 11/28/2016 | Jason B Shandell | Insider | Sell | 26,335 | $20.48 | $539,340.80 | 205,004 | |
| 11/15/2016 | Howard Lee | Director | Sell | 37,994 | $20.65 | $784,576.10 | 134,527 | |
| 10/3/2016 | Floyd F Petersen | Director | Sell | 400 | $18.75 | $7,500.00 | 59,917 | |
| 9/26/2016 | Jason B Shandell | Insider | Sell | 56,996 | $19.50 | $1,111,422.00 | 259,957 | |
| 9/20/2016 | Jack Y Zhang | CEO | Sell | 444,199 | $21.03 | $9,341,504.97 | 1,295,685 | |
| 9/8/2016 | Floyd F Petersen | Director | Sell | 3,000 | $19.05 | $57,150.00 | 60,317 | |
| 9/1/2016 | Howard Lee | Director | Sell | 10,381 | $18.78 | $194,955.18 | 125 | |
| 8/22/2016 | Jason B Shandell | General Counsel | Sell | 10,000 | $19.95 | $199,500.00 | 212,961 | |
| 8/19/2016 | Diane G Gerst | EVP | Sell | 24,046 | $19.28 | $463,606.88 | 39,031 | |
| 8/18/2016 | Richard K Prins | Director | Sell | 3,086 | $19.62 | $60,547.32 | 26,000 | |
| 8/17/2016 | Jason B Shandell | Insider | Sell | 5,987 | $18.86 | $112,914.82 | 202,961 | |
| 8/16/2016 | Stephen B Shohet | Director | Sell | 48,375 | $18.24 | $882,360.00 | 28,653 | |
| 8/15/2016 | Michael A Zasloff | Director | Sell | 48,375 | $18.15 | $878,006.25 | 42,792 | |
| 8/12/2016 | William J Peters | CFO | Sell | 1,027 | $18.19 | $18,681.13 | 63,625 | |
| 8/11/2016 | Jason B Shandell | President | Sell | 5,636 | $18.01 | $101,504.36 | 208,948 | |
| 8/11/2016 | Richard K Prins | Director | Sell | 13,993 | $18.03 | $252,293.79 | 31,681 | |
| 7/18/2016 | William J Peters | CFO | Sell | 2,297 | $17.76 | $40,794.72 | 64,652 | |
| 6/15/2016 | Rong Zhou | EVP | Sell | 1,551 | $15.85 | $24,583.35 | 37,137 | |
| 6/13/2016 | Richard K Prins | Director | Sell | 7,500 | $15.94 | $119,550.00 | 29,086 | |
| 6/9/2016 | Jason B Shandell | President | Sell | 9,904 | $16.43 | $162,722.72 | 216,610 | |
| 6/2/2016 | William J Peters | CFO | Sell | 2,297 | $16.00 | $36,752.00 | 66,949 | |
| 5/25/2016 | Jason B Shandell | President | Sell | 1,074 | $15.60 | $16,754.40 | 226,514 | |
| 5/18/2016 | Diane G Gerst | EVP | Sell | 1,427 | $13.97 | $19,935.19 | 28,649 | |
| 5/17/2016 | Richard K Prins | Director | Sell | 3,200 | $13.56 | $43,392.00 | 23,000 | |
| 4/19/2016 | Diane G Gerst | EVP | Sell | 21,244 | $12.89 | $273,835.16 | 39,713 | |
| 4/18/2016 | Diane G Gerst | EVP | Sell | 15,637 | $12.83 | $200,622.71 | 39,713 | |
| 3/17/2016 | Richard K Prins | Director | Sell | 2,400 | $11.25 | $27,000.00 | 26,200 | |
| 12/17/2015 | Stephen B. Shohet | Director | Sell | 30,770 | $14.19 | $436,626.30 | 12,186 | |
| 12/16/2015 | Howard Lee | Director | Sell | 38,462 | $14.34 | $551,545.08 | 109,901 | |
| 12/16/2015 | Rong Zhou | EVP | Sell | 772 | $14.29 | $11,031.88 | 25,460 | |
| 12/11/2015 | Jack Y Zhang | CEO | Sell | 63,300 | $14.25 | $902,025.00 | 920,117 | |
| 12/8/2015 | Jack Y Zhang | CEO | Sell | 68,117 | $14.71 | $1,002,001.07 | 920,117 | |
| 12/3/2015 | Jack Y Zhang | CEO | Sell | 38,583 | $15.45 | $596,107.35 | 920,117 | |
| 8/18/2015 | Richard K Prins | Director | Sell | 9,100 | $14.66 | $133,406.00 | | |
| 8/17/2015 | Richard K. Prins | Director | Sell | 5,400 | $14.70 | $79,380.00 | 35,722 | |
| 7/17/2015 | Michael A Zasloff | Director | Sell | 7,692 | $17.41 | $133,917.72 | | |
| 6/17/2015 | Rong Zhou | EVP | Sell | 1,000 | $16.48 | $16,480.00 | | |
| 6/15/2015 | Jack Y Zhang | CEO | Sell | 45,382 | $16.29 | $739,272.78 | | |
| 6/12/2015 | Jack Y Zhang | CEO | Sell | 160,495 | $16.23 | $2,604,833.85 | | |
| 6/9/2015 | Jack Y Zhang | CEO | Sell | 193,758 | $16.43 | $3,183,443.94 | | |
| 5/22/2015 | Richard K Prins | Director | Sell | 29,452 | $14.77 | $435,006.04 | | |
| 5/19/2015 | Richard K Prins | Director | Sell | 3,000 | $14.94 | $44,820.00 | | |
| 4/9/2015 | Marilyn J Purchase | VP | Sell | 28,000 | $15.79 | $442,120.00 | | |
| 4/8/2015 | Diane G Gerst | SVP | Sell | 10,000 | $15.79 | $157,900.00 | | |
| 8/25/2014 | Howard Lee | Director | Buy | 6,000 | $10.84 | $65,040.00 | | |
| 8/19/2014 | Michael A Zasloff | Director | Buy | 3,500 | $10.00 | $35,000.00 | | |
| 8/18/2014 | Richard K Prins | Director | Buy | 4,000 | $10.02 | $40,080.00 | | |
| 8/15/2014 | Floyd F Petersen | Director | Buy | 3,200 | $10.35 | $33,120.00 | | |
(Data available from 1/1/2013 forward)
Amphastar Pharmaceuticals (NASDAQ AMPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Analysts Expect Amphastar Pharmaceuticals (AMPH) Will Announce Quarterly Sales of $64.08 Million
www.americanbankingnews.com - May 21 at 2:10 AM |
| Amphastar Pharmaceuticals (AMPH) Expected to Post Earnings of $0.08 Per Share
www.americanbankingnews.com - May 19 at 9:16 PM |
| Amphastar Pharmaceuticals (AMPH) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - May 19 at 1:00 PM |
 | Falling Earnings Estimates Signal Weakness Ahead for Amphastar (AMPH)
finance.yahoo.com - May 18 at 10:41 AM |
| Insider Buying: Amphastar Pharmaceuticals (AMPH) CEO Buys 25,000 Shares of Stock
www.americanbankingnews.com - May 17 at 7:55 PM |
| How Should You Think About Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Risks?
finance.yahoo.com - May 16 at 4:17 PM |
| Amphastar Pharmaceuticals (AMPH) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 4:27 PM |
 | Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway
www.msn.com - May 15 at 10:20 AM |
 | Amphastar Pharmaceuticals' (AMPH) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 4:16 PM |
| FDA OKs Amphastar's generic calcium chloride injection
seekingalpha.com - May 14 at 10:36 AM |
 | BRIEF-Amphastar Pharmaceuticals Receives FDA Approval For Calcium Chloride Injection
www.reuters.com - May 14 at 10:36 AM |
| Edited Transcript of AMPH earnings conference call or presentation 9-May-18 9:00pm GMT
finance.yahoo.com - May 14 at 10:36 AM |
| Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
finance.yahoo.com - May 14 at 10:36 AM |
| Q4 2018 EPS Estimates for Amphastar Pharmaceuticals Increased by Jefferies Group (AMPH)
www.americanbankingnews.com - May 14 at 4:05 AM |
| Amphastar Pharmaceuticals to Post Q3 2018 Earnings of $0.22 Per Share, Piper Jaffray Forecasts (AMPH)
www.americanbankingnews.com - May 14 at 3:13 AM |
| Amphastar Pharmaceuticals (AMPH) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - May 11 at 11:13 AM |
| Amphastar Pharmaceuticals (AMPH) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS
www.americanbankingnews.com - May 10 at 6:12 PM |
| BRIEF-Amphastar Pharmaceuticals Q1 GAAP Loss Per Share $0.16
www.reuters.com - May 10 at 9:55 AM |
 | Amphastar: 1Q Earnings Snapshot
www.cnbc.com - May 10 at 9:55 AM |
| Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
finance.yahoo.com - May 9 at 4:19 PM |
| Zacks: Analysts Anticipate Amphastar Pharmaceuticals (AMPH) Will Announce Quarterly Sales of $60.17 Million
www.americanbankingnews.com - May 4 at 3:40 AM |
| Amphastar Pharmaceuticals (AMPH) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM |
| Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
finance.yahoo.com - May 3 at 4:14 PM |
| $0.09 Earnings Per Share Expected for Amphastar Pharmaceuticals (AMPH) This Quarter
www.americanbankingnews.com - May 2 at 11:25 AM |
| Amphastar Pharmaceuticals (AMPH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 29 at 3:15 PM |
| Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - April 28 at 10:06 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $63.15 Million
www.americanbankingnews.com - April 17 at 4:00 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Earnings of $0.09 Per Share
www.americanbankingnews.com - April 15 at 11:15 AM |
| Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 4 at 5:52 PM |
| What Is Amphastar Pharmaceuticals Inc’s (NASDAQ:AMPH) Share Price Doing?
finance.yahoo.com - April 4 at 5:17 PM |
| Amphastar Pharmaceuticals (AMPH) Downgraded by Raymond James Financial to "Market Perform"
www.americanbankingnews.com - March 31 at 6:34 PM |
| Amphastar Pharmaceuticals Inc (AMPH) Expected to Announce Quarterly Sales of $63.15 Million
www.americanbankingnews.com - March 31 at 3:00 AM |
| Amphastar Pharmaceuticals (AMPH) Downgraded by BidaskClub
www.americanbankingnews.com - March 30 at 9:17 AM |
| Amphastar Pharmaceuticals (AMPH) Presents At Needham and Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:16 PM |
| Analysts Expect Amphastar Pharmaceuticals Inc (AMPH) to Post $0.09 EPS
www.americanbankingnews.com - March 29 at 1:52 PM |
| Is Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) A Sell At Its Current PE Ratio?
finance.yahoo.com - March 28 at 9:57 AM |
 | Amphastar Pharmaceuticals to Present at the Needham's 17th Annual Healthcare Conference
globenewswire.com - March 26 at 4:09 PM |
| Amphastar Pharmaceuticals (AMPH) Earns Buy Rating from Piper Jaffray
www.americanbankingnews.com - March 26 at 1:26 PM |
| Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
finance.yahoo.com - March 26 at 10:11 AM |
 | Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals Inc. and Sandoz Inc.
www.streetinsider.com - March 23 at 9:39 AM |
| Amphastar Pharmaceuticals' (AMPH) Buy Rating Reaffirmed at Wells Fargo
www.americanbankingnews.com - March 22 at 10:54 PM |
| Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:11 PM |
| Head to Head Comparison: Pernix Therapeutics (PTX) vs. Amphastar Pharmaceuticals (AMPH)
www.americanbankingnews.com - March 21 at 1:20 PM |
| Amphastar Pharma (AMPH) Reports Favorable Final Judgement in Patent Litigation Against Momenta Pharmaceuticals ... - StreetInsider.com
www.streetinsider.com - March 21 at 10:55 AM |
 | Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. - Nasdaq
www.nasdaq.com - March 21 at 10:55 AM |
| Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc.
finance.yahoo.com - March 21 at 10:54 AM |
| Jason B. Shandell Sells 20,000 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 20 at 10:14 PM |
| Amphastar Pharmaceuticals (AMPH) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 18 at 7:10 PM |
| Richard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock
www.americanbankingnews.com - March 16 at 7:52 PM |
| Aquinox Pharmaceuticals (AQXP) and Amphastar Pharmaceuticals (AMPH) Head-To-Head Comparison
www.americanbankingnews.com - March 16 at 1:06 PM |
Amphastar Pharmaceuticals (NASDAQ:AMPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amphastar Pharmaceuticals (NASDAQ:AMPH) Income Statement, Balance Sheet and Cash Flow Statement
Amphastar Pharmaceuticals (NASDAQ AMPH) Stock Chart for Monday, May, 21, 2018
Loading chart…
